Hummingbird Medical

Hummingbird Bioscience is a clinical-stage precision biotherapeutics company that leverages its proprietary Rational Antibody Discovery (RAD) platform to develop novel antibody-based therapies for hard-to-drug targets. The company's platform integrates computational biology and systems immunology to identify and target specific, functional epitopes on proteins, enabling the creation of highly differentiated monoclonal and bispecific antibodies. Its lead clinical assets include HMBD-001, an anti-HER3 antibody, and HMBD-002, an anti-VISTA antibody, both of which are currently being evaluated in Phase 1/2 trials for various solid tumors. Headquartered in Singapore with significant operations in Houston and San Francisco, Hummingbird Bioscience also maintains a robust pipeline of next-generation antibody-drug conjugates (ADCs) and has successfully out-licensed several programs to strategic partners.